NZ583192A - Methods for treating dependence - Google Patents
Methods for treating dependenceInfo
- Publication number
- NZ583192A NZ583192A NZ583192A NZ58319208A NZ583192A NZ 583192 A NZ583192 A NZ 583192A NZ 583192 A NZ583192 A NZ 583192A NZ 58319208 A NZ58319208 A NZ 58319208A NZ 583192 A NZ583192 A NZ 583192A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cocaine
- compound
- inhibitor
- patient
- agonist
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- 229940126062 Compound A Drugs 0.000 claims abstract 31
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract 31
- 239000003814 drug Substances 0.000 claims abstract 21
- 208000024891 symptom Diseases 0.000 claims abstract 11
- 239000000126 substance Substances 0.000 claims abstract 7
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 48
- 229960003920 cocaine Drugs 0.000 claims 24
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 24
- 229940079593 drug Drugs 0.000 claims 16
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 12
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 11
- 201000009032 substance abuse Diseases 0.000 claims 11
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 8
- 239000005557 antagonist Substances 0.000 claims 7
- 229960003638 dopamine Drugs 0.000 claims 7
- 230000000306 recurrent effect Effects 0.000 claims 7
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims 6
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims 6
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 6
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 6
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 6
- 239000000674 adrenergic antagonist Substances 0.000 claims 6
- 201000006145 cocaine dependence Diseases 0.000 claims 6
- 206010013663 drug dependence Diseases 0.000 claims 6
- 239000002532 enzyme inhibitor Substances 0.000 claims 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 230000004060 metabolic process Effects 0.000 claims 6
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 6
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 6
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 6
- 230000002093 peripheral effect Effects 0.000 claims 6
- 239000003368 psychostimulant agent Substances 0.000 claims 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 6
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 6
- 229940076279 serotonin Drugs 0.000 claims 6
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 6
- 206010013654 Drug abuse Diseases 0.000 claims 5
- 230000001430 anti-depressive effect Effects 0.000 claims 5
- 239000000935 antidepressant agent Substances 0.000 claims 5
- 229940005513 antidepressants Drugs 0.000 claims 5
- 201000001272 cocaine abuse Diseases 0.000 claims 5
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 4
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical group CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 claims 4
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims 4
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 claims 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims 4
- 230000008033 biological extinction Effects 0.000 claims 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 235000019788 craving Nutrition 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000000380 hallucinogen Substances 0.000 claims 4
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229950002454 lysergide Drugs 0.000 claims 4
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 4
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 3
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 3
- 229940122459 Glutamate antagonist Drugs 0.000 claims 3
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims 3
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims 3
- 241000208125 Nicotiana Species 0.000 claims 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 3
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims 3
- 239000008896 Opium Substances 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 3
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 3
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 3
- 230000001773 anti-convulsant effect Effects 0.000 claims 3
- 230000000561 anti-psychotic effect Effects 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 229960003965 antiepileptics Drugs 0.000 claims 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000000480 calcium channel blocker Substances 0.000 claims 3
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 3
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 claims 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 3
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 3
- 230000003400 hallucinatory effect Effects 0.000 claims 3
- 239000004050 mood stabilizer Substances 0.000 claims 3
- 229940127237 mood stabilizer Drugs 0.000 claims 3
- 229960002715 nicotine Drugs 0.000 claims 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 3
- 239000000181 nicotinic agonist Substances 0.000 claims 3
- 239000003402 opiate agonist Substances 0.000 claims 3
- 239000003401 opiate antagonist Substances 0.000 claims 3
- 229960001027 opium Drugs 0.000 claims 3
- 230000002085 persistent effect Effects 0.000 claims 3
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 claims 3
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 claims 3
- 229940125794 sodium channel blocker Drugs 0.000 claims 3
- 239000003195 sodium channel blocking agent Substances 0.000 claims 3
- 208000011117 substance-related disease Diseases 0.000 claims 3
- 238000003786 synthesis reaction Methods 0.000 claims 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 2
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 claims 2
- GQIVTWIJJVAWQR-DANDVKJOSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid;n-(4-hydroxyphenyl)acetamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CC(=O)NC1=CC=C(O)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC GQIVTWIJJVAWQR-DANDVKJOSA-N 0.000 claims 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 2
- SXPRVMIZFRCAGC-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-methylbenzene Chemical compound CC1=C(F)C(F)=C(F)C(F)=C1F SXPRVMIZFRCAGC-UHFFFAOYSA-N 0.000 claims 2
- WACNXHCZHTVBJM-UHFFFAOYSA-N 1,2,3,4,5-pentafluorobenzene Chemical compound FC1=CC(F)=C(F)C(F)=C1F WACNXHCZHTVBJM-UHFFFAOYSA-N 0.000 claims 2
- PEBWOGPSYUIOBP-UHFFFAOYSA-N 1,2,4-trifluorobenzene Chemical compound FC1=CC=C(F)C(F)=C1 PEBWOGPSYUIOBP-UHFFFAOYSA-N 0.000 claims 2
- GOYDNIKZWGIXJT-UHFFFAOYSA-N 1,2-difluorobenzene Chemical compound FC1=CC=CC=C1F GOYDNIKZWGIXJT-UHFFFAOYSA-N 0.000 claims 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical group CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 241000218236 Cannabis Species 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010008479 Chest Pain Diseases 0.000 claims 2
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims 2
- 206010013954 Dysphoria Diseases 0.000 claims 2
- 208000000059 Dyspnea Diseases 0.000 claims 2
- 206010013975 Dyspnoeas Diseases 0.000 claims 2
- 241001539473 Euphoria Species 0.000 claims 2
- 206010015535 Euphoric mood Diseases 0.000 claims 2
- 206010016059 Facial pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- 206010022998 Irritability Diseases 0.000 claims 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 2
- 208000006550 Mydriasis Diseases 0.000 claims 2
- 206010028735 Nasal congestion Diseases 0.000 claims 2
- 206010052437 Nasal discomfort Diseases 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 206010033557 Palpitations Diseases 0.000 claims 2
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- 208000012886 Vertigo Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 claims 2
- 238000013019 agitation Methods 0.000 claims 2
- 229940025084 amphetamine Drugs 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 230000000949 anxiolytic effect Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 229960001948 caffeine Drugs 0.000 claims 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 2
- 229930003827 cannabinoid Natural products 0.000 claims 2
- 239000003557 cannabinoid Substances 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 229960000632 dexamfetamine Drugs 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 2
- 229960004890 diethylpropion Drugs 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- 208000002173 dizziness Diseases 0.000 claims 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 2
- 208000001780 epistaxis Diseases 0.000 claims 2
- 229960001582 fenfluramine Drugs 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 235000003642 hunger Nutrition 0.000 claims 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 2
- 229960000240 hydrocodone Drugs 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 230000000147 hypnotic effect Effects 0.000 claims 2
- 206010021654 increased appetite Diseases 0.000 claims 2
- 229960003299 ketamine Drugs 0.000 claims 2
- 229940061871 lorcet Drugs 0.000 claims 2
- 229940089568 lortab Drugs 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 229960000299 mazindol Drugs 0.000 claims 2
- 230000003340 mental effect Effects 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- 229960001252 methamphetamine Drugs 0.000 claims 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 2
- 229960001344 methylphenidate Drugs 0.000 claims 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000003158 myorelaxant agent Substances 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 239000000820 nonprescription drug Substances 0.000 claims 2
- 229940078552 o-xylene Drugs 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 230000008058 pain sensation Effects 0.000 claims 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims 2
- 229960000761 pemoline Drugs 0.000 claims 2
- 229940011043 percocet Drugs 0.000 claims 2
- 229950010883 phencyclidine Drugs 0.000 claims 2
- 229960003209 phenmetrazine Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 208000013220 shortness of breath Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 201000006152 substance dependence Diseases 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 229960004380 tramadol Drugs 0.000 claims 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 2
- 229940125725 tranquilizer Drugs 0.000 claims 2
- 239000003204 tranquilizing agent Substances 0.000 claims 2
- 230000002936 tranquilizing effect Effects 0.000 claims 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 2
- 231100000889 vertigo Toxicity 0.000 claims 2
- 229940000146 vicodin Drugs 0.000 claims 2
- 230000008673 vomiting Effects 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 238000009225 cognitive behavioral therapy Methods 0.000 claims 1
- 231100001261 hazardous Toxicity 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- YZZVIKDAOTXDEB-SNVBAGLBSA-N 4-(aminomethyl)-3-[(2r)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1h-imidazole-2-thione Chemical compound NCC1=CNC(=S)N1[C@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-SNVBAGLBSA-N 0.000 abstract 1
- YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US96059107P | 2007-10-04 | 2007-10-04 | |
| PCT/US2008/072357 WO2009021055A1 (en) | 2007-08-06 | 2008-08-06 | Methods for treating dependence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ583192A true NZ583192A (en) | 2012-06-29 |
Family
ID=40341713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ583192A NZ583192A (en) | 2007-08-06 | 2008-08-06 | Methods for treating dependence |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (enExample) |
| EP (2) | EP2182804B1 (enExample) |
| JP (5) | JP2010535801A (enExample) |
| CN (2) | CN101815438A (enExample) |
| AU (1) | AU2008283903B2 (enExample) |
| BR (1) | BRPI0815089A2 (enExample) |
| CA (1) | CA2695372C (enExample) |
| CO (1) | CO6260015A2 (enExample) |
| ES (1) | ES2638190T3 (enExample) |
| IL (1) | IL257418A (enExample) |
| MX (4) | MX391921B (enExample) |
| NZ (1) | NZ583192A (enExample) |
| PH (1) | PH12015502210A1 (enExample) |
| RU (1) | RU2491067C2 (enExample) |
| SG (2) | SG183696A1 (enExample) |
| WO (1) | WO2009021055A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| IL272220B2 (en) | 2017-08-20 | 2024-05-01 | Formulex Pharma Innovations Ltd | Preparations in the form of dry powder to be administered into the nose |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| WO2020212951A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| HRP20230281T1 (hr) * | 2019-11-07 | 2023-04-28 | Small Pharma Ltd | Postupak sinteze |
| WO2021168133A1 (en) * | 2020-02-19 | 2021-08-26 | Nevakar Inc. | Isoproterenol compositions and methods |
| MX2022014605A (es) | 2020-05-19 | 2022-12-16 | Cybin Irl Ltd | Derivados de triptamina deuterada y metodos de uso. |
| MX2023001951A (es) * | 2020-08-17 | 2023-04-21 | Univ Columbia | Uso de imágenes por resonancia magnética (mri) sensibles a la neuromelanina como biomarcador de la función de la dopamina. |
| CN116391128B (zh) * | 2020-10-24 | 2025-11-21 | 巴塞尔大学医院 | 人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| IL305267A (en) | 2021-03-11 | 2023-10-01 | Terran Biosciences Inc | Systems, devices, and methods for harmonization of imaging datasets including biomarkers |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
| IL319304A (en) | 2022-09-16 | 2025-04-01 | Jiangsu Yahong Meditech Co Ltd | Polymorphic form of addition salt of nafixit acid, method for its preparation and use |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03500411A (ja) * | 1987-10-07 | 1991-01-31 | マトリックス テクノロジーズ インコーポレーテッド | コカイン中毒の処置および治療薬 |
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| CA2247468A1 (en) * | 1996-02-23 | 1997-08-28 | Mark Froimowitz | Selective d1 dopamine receptor agonists and partial agonists/antagonists |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| EP1374952B1 (en) * | 2001-01-17 | 2006-09-06 | Hythiam, Inc. | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| AU2002245613A1 (en) * | 2001-03-07 | 2002-09-24 | The Mclean Hospital Corporation | Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| AU2008229203B2 (en) * | 2007-03-16 | 2014-05-29 | Emory University | Methods and compositions for treatment of drug addiction |
| US20090082341A1 (en) * | 2007-07-23 | 2009-03-26 | Synosia Therapeutics | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER |
| CA2707858A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics, Inc. | Treatment of post-traumatic stress disorder |
| US20090054414A1 (en) * | 2007-07-23 | 2009-02-26 | Synosia Therapeutics | Rufinamide for the Treatment of Post-Traumatic Stress Disorder |
| RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| US20100243466A1 (en) | 2007-11-26 | 2010-09-30 | Bridgestone Corporation | Copper-zinc alloy electroplating bath and plating method using the copper-zinc alloy electroplating bath |
-
2008
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ583192A (en) | Methods for treating dependence | |
| JP2010535801A5 (enExample) | ||
| Stack et al. | Monoamine oxidase inhibitors and anaesthesia: a review | |
| US20200368225A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders | |
| JP6332651B2 (ja) | 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物 | |
| WO2007084424A2 (en) | Treatment of substance abuse | |
| US20060258711A1 (en) | Treatment of drug abuse | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| US12257233B2 (en) | Methods | |
| Rehman et al. | Clinical efficacy and safety profile of lofexidine hydrochloride in treating opioid withdrawal symptoms: a review of literature | |
| CN101472571B (zh) | 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用 | |
| Yoon et al. | Antinociceptive effect of intrathecal ginsenosides through α-2 adrenoceptors in the formalin test of rats | |
| MXPA01001180A (es) | Metodos y composiciones para el tratamiento y la prevencion de abuso de sustancias empleando moclobemida. | |
| Werner et al. | Supportive pain therapy in dermatology | |
| AU2003200404B2 (en) | Noribogaine in the treatment of pain and drug addiction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: BIOTIE THERAPIES, US Free format text: OLD OWNER(S): SYNOSIA THERAPEUTICS |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2016 BY CPA GLOBAL Effective date: 20150626 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2017 BY CPA GLOBAL Effective date: 20160624 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2018 BY CPA GLOBAL Effective date: 20170622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2019 BY CPA GLOBAL Effective date: 20180628 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2020 BY CPA GLOBAL Effective date: 20190620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2021 BY CPA GLOBAL Effective date: 20200625 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2022 BY CPA GLOBAL Effective date: 20210624 |
|
| LAPS | Patent lapsed |